Please enable Javascript
Knowledge Hubs
The latest news on genitourinary oncological disease states.
Prostate Cancer Knowledge Hubs
Prostate Cancer
Localized
mCSPC
CRPC
RLT
Prostate Cancer Diagnostics
Prostate Cancer
Localized
mCSPC
CRPC
Advertisement
Renal Cell Carcinoma Knowledge Hubs
Renal Cell Carcinoma
Localized Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
nccRCC
Renal Cell Carcinoma Diagnostics
Renal Cell Carcinoma
Localized Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
nccRCC
Advertisement
Urothelial Carcinoma Knowledge Hubs
Urothelial Carcinoma
Non-Muscle Invasive Urothelial Carcinoma
Muscle Invasive Urothelial Carcinoma
Advanced Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Urothelial Carcinoma Diagnostics
Urothelial Carcinoma
Non-Muscle Invasive Urothelial Carcinoma
Muscle Invasive Urothelial Carcinoma
Advanced Urothelial Carcinoma
Testicular, Penile, and Rare Malignancies Knowledge Hubs
Testicular, Penile, and Rare Malignancies
Testicular, Penile, and Rare Malignancies
Roundtable Discussions
Expert Panel Shares Forward-Looking Thoughts on RCC Treatment, Clinical Trials
Brad McGregor, MD
Renal Cell Carcinoma
|
February 10, 2024
The panel shared their excitement for the road ahead in kidney cancer.
RCC Panel Discusses Treatment Response, Dosing, Patient Management, and More
Brad McGregor, MD
Renal Cell Carcinoma
|
February 10, 2024
The panel addressed different dosing scenarios and shared tips on how to counsel patients on their treatment.
LITESPARK-005 Study Results and Thoughts on Second-Line RCC Treatment
Brad McGregor, MD
Renal Cell Carcinoma
|
February 10, 2024
The panel shared their thoughts on quality of life data presented from the LITESPARK-005 trial of belzutifan.
CheckMate 67T Offers a Look at a Different Treatment Route of Administration
Brad McGregor, MD
Renal Cell Carcinoma
|
February 10, 2024
The panel discussed the impact of a subcutaneous formulation of nivolumab.
Panel Discusses Other RCC Treatment Options: Radiation Techniques, Surgery, and More
Brad McGregor, MD
Renal Cell Carcinoma
|
February 10, 2024
The panel discussed the role of SBRT and some exciting studies like SAMURAI.
CheckMate 9ER: Frontline Nivolumab/Cabozantinib in RCC Patients With Metastases, QOL Considerations
Brad McGregor, MD
Renal Cell Carcinoma
|
February 10, 2024
The panel discussed CheckMate 9ER, which assessed quality of life outcomes in patients receiving cabozantinib/nivolumab.
View Full Archive
Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCO
Editor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MD
Editor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Catherine H. Marshall, MD, MPH
Editor | Assistant Professor of Oncology at the Johns Hopkins University School of Medicine
Jérémie Calais, MD, PhD
Editor | Director of the Theranostics and Clinical Research Programs at the University of California, Los Angeles
Akhil Abraham Saji, MD
Editor | Fellow at the University of Southern California
David Ambinder, MD
Editor | Urology Resident at New York Medical College/Westchester Medical Center